Get the Stockscreener App
12.80
2.40%
0.30
Crescent Biopharma Inc stock is traded at $12.80, with a volume of 212.06K.
It is up +2.40% in the last 24 hours and down -7.18% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$12.50
Open:
$12.25
24h Volume:
212.06K
Relative Volume:
2.02
Market Cap:
$173.66M
Revenue:
$6.67M
Net Income/Loss:
$-47.55M
P/E Ratio:
-8.5333
EPS:
-1.5
Net Cash Flow:
$-17.44M
1W Performance:
+4.66%
1M Performance:
-7.18%
6M Performance:
+2,403%
1Y Performance:
+2,403%
1-Day Range:
$12.25
$13.21
1-Week Range:
$12.03
$13.21
52-Week Range:
$10.83
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
12.80 | 173.66M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.15 | 100.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.50 | 60.95B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.73 | 60.46B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
734.35 | 46.04B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.20 | 36.02B | 3.81B | -644.79M | -669.77M | -6.24 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
With 36% stake, Crescent Biopharma, Inc. (NASDAQ:CBIO) seems to have captured institutional investors' interest - uk.finance.yahoo.com
Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Jefferies Initiates Crescent Biopharma(CBIO.US) With Buy Rating, Announces Target Price $26 - 富途牛牛
Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above 200-Day Moving AverageTime to Sell? - MarketBeat
Analysts Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Price Target at $25.60 - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma to Present at September Investor Conferences - AInvest
Crescent Biopharma (NASDAQ:CBIO) Coverage Initiated by Analysts at Jefferies Financial Group - MarketBeat
LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - 富途牛牛
Crescent Biopharma (NASDAQ:CBIO) Given Buy Rating at HC Wainwright - Defense World
Cancer Drug Developer Crescent Biopharma to Present at Major September Healthcare Conferences - Stock Titan
Stifel reiterates Buy rating on Crescent Biopharma stock at $28 target - Investing.com
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - AInvest
This Devon Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Jefferies Initiates Coverage of Crescent Biopharma with Buy Rating and $26 Price Target - AInvest
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates coverage on Crescent Biopharma stock with Buy rating - Investing.com
Crescent Biopharma shares rise 3.70% intraday after Pyxis Oncology CEO to participate in September investor conferences. - AInvest
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving Average – What’s Next? - Defense World
Crescent Biopharma: Chasing The Summit Hype - Seeking Alpha
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $25.50 Consensus Target Price from Analysts - Defense World
Q3 Earnings Forecast for CBIO Issued By HC Wainwright - Defense World
HC Wainwright Initiates Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Crescent Biopharma Initiated with Buy Rating and $25 Price Target by H.C. Wainwright - AInvest
Analysts Initiate Coverage on Arm Holdings with Bullish Predictions - AInvest
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday - Benzinga
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27 - 富途牛牛
Crescent Biopharma (NASDAQ:CBIO) Cut to “Sell” at Wall Street Zen - Defense World
Crescent Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Crescent Biopharma: Q2 Earnings Snapshot - Greenwich Time
Crescent Biopharma Advances Cancer Therapeutics with CR-001 and ADCs, Completes Merger and Nasdaq Listing - AInvest
Crescent Biopharma's Promising Pipeline and Strategic Positioning Support Buy Rating - AInvest
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView
Crescent Biopharma Raises $200M to Accelerate Next-Gen Cancer Therapies Development Following Strategic Merger - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Upgraded by Wall Street Zen - Defense World
What is Wedbush’s Estimate for CBIO Q2 Earnings? - Defense World
Wedbush Begins Coverage on Crescent Biopharma (NASDAQ:CBIO) - Defense World
Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener
Wedbush Initiates Coverage of Crescent Biopharma (CBIO) with Outperform Recommendation - MSN
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Sell Rating - Defense World
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Galectin Therapeutics shares rise 3.30% premarket after Crescent Biopharma appoints new Chief Scientific Officer. - AInvest
Crescent Biopharma Snatches Oncology Star Jan Pinkas—Here's Why This Could Be a Game-Changer - AInvest
Crescent Biopharma appoints Jan Pinkas as chief scientific officer - Investing.com
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer - GlobeNewswire
ADC Pioneer with ELAHERE Success Record Joins Crescent Biopharma as Chief Scientific Officer - Stock Titan
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):